ATE533485T1 - Cetp-inhibitoren - Google Patents

Cetp-inhibitoren

Info

Publication number
ATE533485T1
ATE533485T1 AT06826999T AT06826999T ATE533485T1 AT E533485 T1 ATE533485 T1 AT E533485T1 AT 06826999 T AT06826999 T AT 06826999T AT 06826999 T AT06826999 T AT 06826999T AT E533485 T1 ATE533485 T1 AT E533485T1
Authority
AT
Austria
Prior art keywords
cetp inhibitors
cholesterol
compounds
treating
useful
Prior art date
Application number
AT06826999T
Other languages
English (en)
Inventor
Amjad Ali
Julianne Hunt
Florida Kallashi
Jennifer Kowalchick
Dooseop Kim
Cameron Smith
Peter Sinclair
Ramzi Sweis
Gayle Taylor
Christopher Thompson
Liya Chen
Nazia Quraishi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE533485(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE533485T1 publication Critical patent/ATE533485T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06826999T 2005-10-31 2006-10-30 Cetp-inhibitoren ATE533485T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73216805P 2005-10-31 2005-10-31
PCT/US2006/042208 WO2007070173A2 (en) 2005-10-31 2006-10-30 Cetp inhibitors

Publications (1)

Publication Number Publication Date
ATE533485T1 true ATE533485T1 (de) 2011-12-15

Family

ID=38163381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06826999T ATE533485T1 (de) 2005-10-31 2006-10-30 Cetp-inhibitoren

Country Status (7)

Country Link
US (1) US8334290B2 (de)
EP (1) EP1954287B2 (de)
JP (1) JP5301999B2 (de)
AT (1) ATE533485T1 (de)
AU (1) AU2006325294B2 (de)
CA (1) CA2627722A1 (de)
WO (1) WO2007070173A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
AU2007235577B2 (en) 2006-03-31 2011-09-15 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor
CN101626765B (zh) * 2006-06-23 2012-12-26 帕拉特克药品公司 转录因子调节化合物及其使用方法
JP2010530416A (ja) * 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
JP2010530418A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
CA2689523A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
BRPI0814182A2 (pt) * 2007-08-02 2015-01-27 Recordati Ireland Ltd Compostos heterocíclocos inéditos como antagonistas de mglu5
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
MX2013000359A (es) 2010-07-09 2013-02-11 Ube Industries Compuesto de piridina sustituida.
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
JPWO2013027694A1 (ja) * 2011-08-24 2015-03-19 国立大学法人京都大学 コンフォメーション病診断用分子イメージングプローブ
CN102977085B (zh) * 2011-10-27 2015-07-29 四川大学 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途
CA2860601C (en) 2012-01-06 2016-07-05 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
US9688630B2 (en) 2013-10-10 2017-06-27 Merck Sharp & Dohme Corp. 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
US9663534B2 (en) 2013-12-17 2017-05-30 Merck Sharp & Dohme Corp. Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
EP3174537B1 (de) 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclische isoxazoline als hemmer des cholesterinestertransferproteins
US20170298081A1 (en) * 2014-08-08 2017-10-19 Kasuma Partners Inc. Condensed heterocyclic compound
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
KR20160066490A (ko) 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
WO2016089062A2 (en) * 2014-12-02 2016-06-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR102440762B1 (ko) * 2016-07-07 2022-09-05 호도가야 가가쿠 고교 가부시키가이샤 벤조아졸 고리 구조를 가지는 화합물 및 유기 일렉트로루미네센스 소자
JP7028889B2 (ja) 2016-12-20 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー テトラヒドロカルバゾールカルボキサミド化合物の製造方法
CN106928212B (zh) * 2017-02-28 2020-03-17 牡丹江医学院 一种用于治疗阑尾炎的药物及其制备方法和应用
KR102101234B1 (ko) * 2017-04-18 2020-04-16 부산대학교 산학협력단 신규 sirt 1 활성화제 및 이의 의학적 용도
WO2018205916A1 (zh) * 2017-05-09 2018-11-15 南京圣和药业股份有限公司 Fgfr4抑制剂及其制备与应用
KR102009325B1 (ko) * 2018-03-29 2019-08-09 한림대학교 산학협력단 노카벤즈옥사졸 유도체 합성방법 및 그 유도체를 포함하는 항염증 약학 조성물
KR101997518B1 (ko) * 2018-03-29 2019-10-01 한림대학교 산학협력단 노카벤즈옥사졸 g 및 노카벤즈옥사졸 유도체 합성방법
KR101997516B1 (ko) * 2018-03-29 2019-10-01 한림대학교 산학협력단 노카벤즈옥사졸 및 그 유도체 합성방법
WO2020077024A1 (en) 2018-10-10 2020-04-16 Albert Einstein College Of Medicine Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
TR201904869A2 (tr) * 2019-04-01 2020-10-21 Anadolu Ueniversitesi Anti-kanser etkili benzoksazol türevi bileşikler.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
JP2023551474A (ja) * 2020-11-25 2023-12-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症の処置および予防のための芳香族架橋環アミド誘導体
CN116262744A (zh) * 2021-12-13 2023-06-16 复旦大学 用于α-突触核蛋白聚集体成像的小分子探针
AU2023418987A1 (en) * 2022-12-30 2025-07-03 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612776A (de) * 1961-01-19
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
CH597225A5 (de) * 1974-08-14 1978-03-31 Ciba Geigy Ag
LU76819A1 (de) * 1977-02-22 1978-10-18
DE3307364A1 (de) † 1983-03-02 1984-09-06 Hoechst Ag, 6230 Frankfurt Zweikomponenten-diazontypiematerial
DE3818986A1 (de) * 1987-06-05 1988-12-22 Ciba Geigy Ag Transparente folie
US5104960A (en) * 1989-02-22 1992-04-14 The Dow Chemical Company Nucleophilic displacement method for synthesis of non-rigid PBZ polymers
US6372770B1 (en) * 1994-10-12 2002-04-16 Euro-Celtique, S.A. Benzoxazoles
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
US6184235B1 (en) † 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
IT1284525B1 (it) * 1996-09-13 1998-05-21 3V Sigma Spa Derivati di benzossazolo loro uso come stabilizzanti contro le radiazioni uv
EP0986384B1 (de) * 1997-05-07 2012-02-22 University Of Pittsburgh Isoprentransferase proteine inhibitoren
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
MXPA00011470A (es) † 1998-05-22 2002-10-17 Avanir Pharmaceuticals Analogos de bencimidazol como reguladores de la disminucion de ige.
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
WO2001052847A1 (en) * 2000-01-19 2001-07-26 Alteon, Inc. Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
CZ2003686A3 (cs) * 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
WO2002036580A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
JP2004359546A (ja) 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
CA2444214A1 (en) † 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
US20040006092A1 (en) 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
DE10204115A1 (de) * 2002-02-01 2003-08-07 Bayer Cropscience Ag DELTA·1·-Pyrroline
EP1482931B1 (de) * 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
TW200304820A (en) † 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
SE0202462D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
AU2003264407A1 (en) † 2002-09-18 2004-04-08 Mitsui Mining And Smelting Co., Ltd. Electronic component burning jig
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
AU2003283597A1 (en) 2002-11-16 2004-06-15 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
CA2438032C (en) † 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1628967B1 (de) * 2003-05-19 2014-04-09 Irm Llc Die immunreaktion unterdrückende verbindungen und zusammensetzungen
EP1663959A4 (de) * 2003-09-05 2007-10-31 Univ North Carolina Neue amidinverbindungen zur behandlung mikrobieller infektionen
WO2005030206A1 (en) † 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
GB0326964D0 (en) 2003-11-19 2003-12-24 Glaxo Group Ltd Chemical compounds
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
CA2589877A1 (en) † 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
EP1861387B1 (de) † 2005-01-28 2014-04-16 Daewoong Pharmaceutical Co., Ltd. Benzimidazol-derivate und deren pharmazeutische zusammensetzungen
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
WO2007039170A1 (en) * 2005-09-23 2007-04-12 European Molecular Biology Laboratory (Embl) Antagonists of topoisomerase activity and their use in inhibiting pathological conditions
UY29825A1 (es) † 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
AU2007235577B2 (en) † 2006-03-31 2011-09-15 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor

Also Published As

Publication number Publication date
JP5301999B2 (ja) 2013-09-25
US20090264405A1 (en) 2009-10-22
WO2007070173A2 (en) 2007-06-21
EP1954287B2 (de) 2016-02-24
US8334290B2 (en) 2012-12-18
JP2009516649A (ja) 2009-04-23
CA2627722A1 (en) 2007-06-21
AU2006325294B2 (en) 2012-10-11
EP1954287B1 (de) 2011-11-16
WO2007070173A3 (en) 2009-05-07
EP1954287A4 (de) 2010-05-05
EP1954287A2 (de) 2008-08-13
AU2006325294A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
EP1954287A4 (de) Cetp-inhibitoren
GEP20094694B (en) Cetp inhibitors
TN2014000158A1 (en) Fused bicyclic oxazolidinone cetp inhibitor
WO2007081571A3 (en) Cetp inhibitors
MX2009009290A (es) Compuestos activos en ppar.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2007081569A3 (en) Cetp inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
WO2007081570A3 (en) Cholesteryl ester transfer protein inhibitors
WO2007079186A3 (en) 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
TW200745028A (en) Novel sulphonylpyrroles
MX2014001023A (es) Derivados de quinazolina.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
UA107689C2 (xx) ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ
TW200745027A (en) Novel sulphonylpyrroles
NO20081292L (no) Pentasykliske kinaseinhibitorer
MX2010000918A (es) Derivado de bencimidazol.